INTRODUCTION: Asthma is one of the serious global health problems and cause of huge mortality and morbidity. It is characterized by persistent airway inflammation, airway hyperresponsiveness, increased IgE levels and mucus hypersecretion. Asthma is mediated by dominant Th2 immune response, causing enhanced expression of Th2 cytokines. These cytokines are responsible for the various pathological changes associated with allergic asthma. MATERIALS AND METHODS: The role of Th2 cells in the pathogenesis of the asthma is primarily mediated through the cytokine IL-13, also produced by type 2 innate lymphoid cells, that comes under the transcriptional regulation of GATA3. In this review we will try to explore the link between IL-13 and GATA3 in the progression and regulation of asthma and its possible role as a therapeutic target. CONCLUSION: Inhibition of GATA3 activity or blockade of GATA3 expression may attenuate the interleukin-13 mediated asthma phenotypes. So, GATA3 might be a potential therapeutic target for the treatment of allergic asthma.
INTRODUCTION:Asthma is one of the serious global health problems and cause of huge mortality and morbidity. It is characterized by persistent airway inflammation, airway hyperresponsiveness, increased IgE levels and mucus hypersecretion. Asthma is mediated by dominant Th2 immune response, causing enhanced expression of Th2 cytokines. These cytokines are responsible for the various pathological changes associated with allergic asthma. MATERIALS AND METHODS: The role of Th2 cells in the pathogenesis of the asthma is primarily mediated through the cytokine IL-13, also produced by type 2 innate lymphoid cells, that comes under the transcriptional regulation of GATA3. In this review we will try to explore the link between IL-13 and GATA3 in the progression and regulation of asthma and its possible role as a therapeutic target. CONCLUSION: Inhibition of GATA3 activity or blockade of GATA3 expression may attenuate the interleukin-13 mediated asthma phenotypes. So, GATA3 might be a potential therapeutic target for the treatment of allergic asthma.
Authors: Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy Journal: Am J Respir Crit Care Med Date: 2009-05-29 Impact factor: 21.405
Authors: Xin Yao; Wangjian Zha; Wei Song; Haiyan He; Mao Huang; Elen Jazrawi; Paul Lavender; Peter J Barnes; Ian M Adcock; Andrew L Durham Journal: Biochem Biophys Res Commun Date: 2011-12-27 Impact factor: 3.575
Authors: A Heinzmann; X Q Mao; M Akaiwa; R T Kreomer; P S Gao; K Ohshima; R Umeshita; Y Abe; S Braun; T Yamashita; M H Roberts; R Sugimoto; K Arima; Y Arinobu; B Yu; S Kruse; T Enomoto; Y Dake; M Kawai; S Shimazu; S Sasaki; C N Adra; M Kitaichi; H Inoue; K Yamauchi; N Tomichi; F Kurimoto; N Hamasaki; J M Hopkin; K Izuhara; T Shirakawa; K A Deichmann Journal: Hum Mol Genet Date: 2000-03-01 Impact factor: 6.150
Authors: M P McLane; A Haczku; M van de Rijn; C Weiss; V Ferrante; D MacDonald; J C Renauld; N C Nicolaides; K J Holroyd; R C Levitt Journal: Am J Respir Cell Mol Biol Date: 1998-11 Impact factor: 6.914
Authors: Roel G J Klein Wolterink; Nicolas Serafini; Menno van Nimwegen; Christian A J Vosshenrich; Marjolein J W de Bruijn; Diogo Fonseca Pereira; Henrique Veiga Fernandes; Rudi W Hendriks; James P Di Santo Journal: Proc Natl Acad Sci U S A Date: 2013-06-03 Impact factor: 11.205
Authors: Kim A T Verheijden; Saskia Braber; Thea Leusink-Muis; Prescilla V Jeurink; Suzan Thijssen; Aletta D Kraneveld; Johan Garssen; Gert Folkerts; Linette E M Willemsen Journal: Front Immunol Date: 2018-10-23 Impact factor: 7.561
Authors: Suzanne Abbring; Kim A T Verheijden; Mara A P Diks; Athea Leusink-Muis; Gert Hols; Ton Baars; Johan Garssen; Betty C A M van Esch Journal: Front Immunol Date: 2017-08-28 Impact factor: 7.561